Keyword: Mayzent (siponimod)
A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.
Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.
Zolgensma hauled in $160 million in its first full quarter on the market, more than 60% above the Street's expectations.
A post hoc analysis found 75% of patients showed no increase in disability five years after treatment with Mavenclad.
Novartis is working to change doctors’ “psychology” around SPMS treatment. And new disability data for its drug, Mayzent, should help its case.
Patients on Ocrevus saw their blood neurofilament light chain level lowered to a healthy donor range in phase 3 studies, Roche said.
ICER has ruled that neither Novartis' $88,500 MS drug Mayzent nor J&J's $32,400 depression spray Spravato is cost effective.
New analysis found Mayzent had meaningful benefits on cognitive processing speed in patients with secondary progressive multiple sclerosis.
Novartis officially has approval for Mayzent to treat patients with secondary progressive multiple sclerosis.